Document is current
Any future updates will be listed below
-
Authors
Muchtar, E
Dingli, D
Kumar, S
Buadi, F K
Dispenzieri, A
Hayman, S R
Wolf, R C
Gastineau, D A
Chakraborty, R
Hogan, W J
Leung, N
Kapoor, P
Lacy, M Q
Rajkumar, S V
Gertz, M A
- License Information
-
More Information
Article History
Received: 15 March 2016
Revised: 9 May 2016
Accepted: 17 May 2016
First Online: 4 July 2016
Competing interests
: SK: Celgene Corp. (consultancy and research funding), Millennium Pharmaceuticals Inc. (consultancy and research funding), Novartis International AG (research funding), Onyx Pharmaceuticals Inc. (consultancy and research funding), AbbVie Inc. (research funding), Janssen Pharmaceuticals, Inc. (consultancy and research funding) and Bristol-Myers Squibb Co. (consultancy and research funding); AD: Celgene Corp (research funding), Millennium Pharmaceuticals Inc. (research funding), Pfizer Inc. (research funding and travel grant) and Janssen Pharmaceuticals Inc. (research funding); PK: Millennium Pharmaceuticals Inc. (Takeda Pharmaceutical Co. Limited) (research funding), Celgene Corp. (research funding) and Onyx Pharmaceuticals Inc. (Amgen Inc.) (research funding); MQL: Celgene Corp. (research funding); MAG: Celgene Corp (honoraria), Millennium Pharmaceuticals, Inc. (consultancy and honoraria), Onyx Pharmaceuticals Inc. (honoraria), Novartis International AG (honoraria) and GlaxoSmithKline PLC (honoraria). The remaining authors declare no conflict of interest.
